{"id":"mg-cl","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal cramping"}]},"_chembl":{"chemblId":"CHEMBL5314922","moleculeType":"Small molecule","molecularWeight":"436.52"},"_dailymed":{"setId":"c907301d-e24d-9609-5529-fed14f94549f","title":"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 5 MG,CLL) TABLET DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 7.5 MG,CLL) TABLET DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 10 MG,CLL) TABLET DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 12.5 MG,CLL) TABLET DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 15 MG,CLL) TABLET DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 20 MG,CLL) TABLET DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 30 MG,CLL) TABLET [ALVOGEN INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Magnesium is an essential cofactor for numerous enzymatic reactions and is critical for neuromuscular function, cardiac rhythm, and protein synthesis. Magnesium chloride provides bioavailable magnesium ions to correct deficiency states. It is commonly used as a supplement or therapeutic agent to treat hypomagnesemia and related conditions.","oneSentence":"Magnesium chloride is an electrolyte replacement that restores depleted magnesium levels in the body.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:01:07.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Magnesium deficiency (hypomagnesemia)"},{"name":"Magnesium supplementation"}]},"trialDetails":[{"nctId":"NCT07497009","phase":"NA","title":"Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial.","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-12-23","conditions":"Neurocognitive Function of Elderly Patients Post Operation","enrollment":30},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT06223568","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-10","conditions":"Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses","enrollment":70},{"nctId":"NCT05462730","phase":"PHASE2","title":"Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Thomas Engstrom","startDate":"2022-11-14","conditions":"ST Elevation Myocardial Infarction, Inflammatory Response, Myocardial Reperfusion Injury","enrollment":530},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT01846390","phase":"PHASE1","title":"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2013-10-01","conditions":"Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":21},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT06406465","phase":"PHASE2","title":"A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine","enrollment":60},{"nctId":"NCT06917404","phase":"PHASE3","title":"A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.","status":"RECRUITING","sponsor":"Paradigm Biopharmaceuticals Ltd.","startDate":"2025-05-29","conditions":"Osteoarthritis, Knee","enrollment":466},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT06788756","phase":"PHASE2, PHASE3","title":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML","status":"RECRUITING","sponsor":"Moleculin Biotech, Inc.","startDate":"2025-03-12","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":312},{"nctId":"NCT05555732","phase":"PHASE3","title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2023-01-11","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":1170},{"nctId":"NCT03336398","phase":"PHASE2","title":"Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-09-01","conditions":"Tinnitus","enrollment":42},{"nctId":"NCT04959123","phase":"NA","title":"Does the Common Practice of Adding Diluted Epinephrine in Tranverse Abdominal Plan Block to Ropivacaine Significantly Decrease the Peak Systemic Resorption of Ropivacaine?","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2021-12-06","conditions":"Bowel Disease","enrollment":40},{"nctId":"NCT06126224","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2023-08-28","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":500},{"nctId":"NCT07486544","phase":"PHASE3","title":"Soaked Pharyngeal Packing Agents in Septoplasty","status":"RECRUITING","sponsor":"Assiut University","startDate":"2026-03-20","conditions":"Sore Throat","enrollment":90},{"nctId":"NCT04823585","phase":"PHASE4","title":"Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2021-08-12","conditions":"Asthma, Aspirin-Induced, Chronic Rhinosinusitis With Nasal Polyps","enrollment":95},{"nctId":"NCT07489651","phase":"PHASE2","title":"RE104 Safety and Efficacy Study in Generalized Anxiety Disorder","status":"NOT_YET_RECRUITING","sponsor":"Reunion Neuroscience Inc","startDate":"2026-04","conditions":"Generalized Anxiety Disorder","enrollment":64},{"nctId":"NCT07490002","phase":"PHASE2","title":"Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-04-06","conditions":"Esophageal Squamous Carcinoma","enrollment":33},{"nctId":"NCT05980949","phase":"PHASE3","title":"Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2023-07-11","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":800},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT03410615","phase":"PHASE2","title":"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-05-28","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":129},{"nctId":"NCT05511363","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2022-08-23","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":410},{"nctId":"NCT04003636","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-24","conditions":"Biliary Tract Carcinoma","enrollment":1069},{"nctId":"NCT02422498","phase":"PHASE2","title":"Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-04-14","conditions":"Locally Recurrent/Metastatic Triple Negative Breast Cancer","enrollment":49},{"nctId":"NCT07392541","phase":"PHASE1, PHASE2","title":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Carcinoma","enrollment":29},{"nctId":"NCT02997332","phase":"PHASE1","title":"Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-03-30","conditions":"Head and Neck Cancers","enrollment":14},{"nctId":"NCT06634030","phase":"PHASE2","title":"Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-04-01","conditions":"Wound Healing, Surgical Wound","enrollment":40},{"nctId":"NCT05586009","phase":"PHASE2","title":"Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-01","conditions":"Cisplatin Adverse Reaction","enrollment":100},{"nctId":"NCT07488988","phase":"PHASE2","title":"SCARFREE-001: Verteporfin for Scar Prevention","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","startDate":"2026-06","conditions":"Surgical Scar","enrollment":12},{"nctId":"NCT07488832","phase":"NA","title":"Intravenous Lidocaine Infusion in Lumbar Fusion Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2026-03-20","conditions":"Lumbar Fusion Surgery","enrollment":110},{"nctId":"NCT07125755","phase":"PHASE3","title":"Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-15","conditions":"Squamous Cell Cancer of Head and Neck (SCCHN)","enrollment":386},{"nctId":"NCT05911295","phase":"PHASE3","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-09-22","conditions":"Urothelial Carcinoma","enrollment":412},{"nctId":"NCT07224711","phase":"PHASE4","title":"The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-07-01","conditions":"Pain, Post Operative Analgesia, Opioid Consumption, Postoperative","enrollment":2290},{"nctId":"NCT07481058","phase":"PHASE2","title":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2025-12-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT04763343","phase":"PHASE3","title":"Ketamine Treatment of Youth Suicide Attempters","status":"RECRUITING","sponsor":"Tatiana Falcone, MD","startDate":"2022-06-27","conditions":"Suicide, Attempted","enrollment":60},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT05681884","phase":"PHASE2","title":"Safety and Efficacy of Faricimab in Patients With NPDR","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2023-05-16","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":179},{"nctId":"NCT06229483","phase":"PHASE3","title":"The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies","status":"RECRUITING","sponsor":"Stephen Lownie","startDate":"2024-04-03","conditions":"Brain Tumor, Bleeding","enrollment":102},{"nctId":"NCT04614714","phase":"PHASE2, PHASE3","title":"Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-04-01","conditions":"Preterm Birth, Inadequate Milk Production","enrollment":40},{"nctId":"NCT06301880","phase":"PHASE3","title":"Effect of Topically-applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow","status":"COMPLETED","sponsor":"Damascus University","startDate":"2022-01-01","conditions":"Internal Mammary Artery Syndrome, Vasodilation","enrollment":46},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT07483346","phase":"PHASE1","title":"IASO-782 in Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Shanghai IASO Biotechnology Co., Ltd","startDate":"2026-04-30","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT05789082","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-20","conditions":"Non-Small Cell Lung Cancer","enrollment":320},{"nctId":"NCT07129993","phase":"PHASE2, PHASE3","title":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-09-26","conditions":"Urothelial Cancer, Bladder Cancer","enrollment":630},{"nctId":"NCT06426823","phase":"NA","title":"The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2023-11-01","conditions":"Blood Flow","enrollment":10},{"nctId":"NCT07469722","phase":"PHASE2, PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":"Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect","enrollment":128},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT06408597","phase":"NA","title":"Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nazmy Edward Seif","startDate":"2024-05-12","conditions":"Prostate Cancer, Bladder Cancer, Surgery","enrollment":90},{"nctId":"NCT06599307","phase":"PHASE2","title":"The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-08-01","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":46},{"nctId":"NCT07434024","phase":"NA","title":"Erector Spinae Plane Block for Acute Low Back Pain","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-03","conditions":"Non-specific Low Back Pain (NSLBP)","enrollment":300},{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT07315074","phase":"NA","title":"Effect of Esketamine on Postoperative Sleep in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Zhuan Zhang","startDate":"2026-03-01","conditions":"Circadian Rhythm, Postoperative Sleep Disturbance","enrollment":164},{"nctId":"NCT06728761","phase":"NA","title":"Gastric Emptying With Trou Normand","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2025-12-19","conditions":"Healthy Volunteer","enrollment":8},{"nctId":"NCT07221253","phase":"PHASE3","title":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-04","conditions":"Biliary Tract Cancer","enrollment":1100},{"nctId":"NCT04587791","phase":"EARLY_PHASE1","title":"Cannabidiol in Opioid Use Disorder and Chronic Pain","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-12-08","conditions":"Chronic Pain, Opioid Use Disorder","enrollment":34},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT03547973","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2018-08-13","conditions":"Metastatic Urothelial Cancer","enrollment":827},{"nctId":"NCT07459296","phase":"PHASE3","title":"Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-03-05","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":266},{"nctId":"NCT07474909","phase":"NA","title":"Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery","status":"NOT_YET_RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2026-04-01","conditions":"Hand Injuries and Disorders, Wrist Sprain","enrollment":150},{"nctId":"NCT06966778","phase":"NA","title":"Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-15","conditions":"Localized Prostate Cancer, Postoperative Urinary Incontinence","enrollment":135},{"nctId":"NCT04389632","phase":"PHASE1","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-06-08","conditions":"Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms","enrollment":1006},{"nctId":"NCT07475286","phase":"PHASE2","title":"Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis","status":"NOT_YET_RECRUITING","sponsor":"Mohammad Haroon Asif Choudry","startDate":"2026-04-30","conditions":"Synchronous Gastric Peritoneal Carcinomatosis, Gastroesophageal Peritoneal Carcinomatosis","enrollment":22},{"nctId":"NCT01631617","phase":"PHASE2","title":"Effects of Treatments on Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2012-09-18","conditions":"Eczema, Dermatitis, Skin Diseases, Genetic","enrollment":130},{"nctId":"NCT07472270","phase":"PHASE1","title":"Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2026-03-15","conditions":"Liver Cirrhosis","enrollment":12},{"nctId":"NCT04459117","phase":"PHASE2, PHASE3","title":"Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-10-29","conditions":"Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity","enrollment":804},{"nctId":"NCT07469332","phase":"NA","title":"Comparison of the Effects of Moderate- and High-Dose Glucocorticoids on Postoperative Recovery","status":"NOT_YET_RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2026-03-30","conditions":"Postoperative Recovery, PONV","enrollment":135},{"nctId":"NCT07216430","phase":"PHASE2","title":"Safety and Efficacy of wSp Vaccine in Young Children","status":"RECRUITING","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-09-29","conditions":"Acute Otitis Media (AOM)","enrollment":320},{"nctId":"NCT02726711","phase":"PHASE1","title":"Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2016-04","conditions":"Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension","enrollment":2},{"nctId":"NCT00421096","phase":"PHASE2","title":"Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2005-05","conditions":"Uterine Cervical Cancer","enrollment":19},{"nctId":"NCT04468659","phase":"PHASE3","title":"AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-07-14","conditions":"Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease","enrollment":1400},{"nctId":"NCT05687266","phase":"PHASE3","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-29","conditions":"NSCLC","enrollment":1350},{"nctId":"NCT05521997","phase":"PHASE2","title":"Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-07-31","conditions":"Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer","enrollment":42},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT04457284","phase":"PHASE2","title":"Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-18","conditions":"Colorectal Adenocarcinoma","enrollment":18},{"nctId":"NCT06252623","phase":"PHASE1","title":"Exenatide For Reducing the Reinforcing Effects of Cocaine","status":"WITHDRAWN","sponsor":"Christopher D. Verrico","startDate":"2024-08-01","conditions":"Cocaine Use Disorder","enrollment":""},{"nctId":"NCT04521881","phase":"PHASE3","title":"Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-04-18","conditions":"Traumatic Brain Injury","enrollment":5000},{"nctId":"NCT06959082","phase":"PHASE2","title":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","status":"RECRUITING","sponsor":"VSPharmTech Co.,Ltd.","startDate":"2026-03","conditions":"Head and Neck Cancer Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05304767","phase":"PHASE3","title":"An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2022-03-07","conditions":"Schizophrenia","enrollment":280},{"nctId":"NCT06687369","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)","status":"RECRUITING","sponsor":"mAbxience Research S.L.","startDate":"2024-12-30","conditions":"Non Squamous Non Small Cell Lung Cancer","enrollment":726},{"nctId":"NCT07463313","phase":"PHASE2, PHASE3","title":"6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":"Thymoma and Thymic Carcinoma","enrollment":116},{"nctId":"NCT07103746","phase":"PHASE2","title":"Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-26","conditions":"Autoimmune Disorders","enrollment":30},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT04832854","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-23","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":50},{"nctId":"NCT06862609","phase":"NA","title":"QIPB in Inguinal Hernia","status":"RECRUITING","sponsor":"Konya City Hospital","startDate":"2025-03-23","conditions":"Postoperative Pain","enrollment":70},{"nctId":"NCT06059846","phase":"PHASE3","title":"A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2023-12-21","conditions":"Urinary Tract Infection, Acute Pyelonephritis","enrollment":1690},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT06783309","phase":"PHASE1, PHASE2","title":"CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)","status":"RECRUITING","sponsor":"COUR Pharmaceutical Development Company, Inc.","startDate":"2025-05-12","conditions":"Type 1 Diabetes Mellitus, T1D, T1DM","enrollment":72},{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT04828083","phase":"PHASE4","title":"Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Rhode Island Hospital","startDate":"2021-03-01","conditions":"Arthroplasty, Replacement, Knee, Total Knee Arthroplasty","enrollment":120},{"nctId":"NCT05689671","phase":"PHASE4","title":"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nikolaj Frost MD","startDate":"2023-12-06","conditions":"Non-Small Cell Lung Cancer Metastatic","enrollment":136},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":464,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mg Cl","genericName":"Mg Cl","companyName":"University of Vermont","companyId":"university-of-vermont","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Magnesium chloride is an electrolyte replacement that restores intracellular and extracellular magnesium levels. Used for Magnesium deficiency (hypomagnesemia), Hypomagnesemia secondary to diuretic use or gastrointestinal loss.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}